Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 1/20 | 0.55 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 4/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | KAT7 | O95251 | 1/20 | 0.45 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1624362 | 1.00 | JAK2 (0.55) | JAK2JAK1ACKR3HTR6USP30 | |
| SCHEMBL1624057 | 1.00 | JAK2 (0.55) | JAK2JAK1ACKR3HTR6USP30 | |
| SCHEMBL1623986 | 0.93 | JAK2 (0.60) | JAK2JAK1USP30GPR119STS | |
| SCHEMBL15462496 | 0.93 | JAK2 (0.60) | JAK2JAK1USP30GPR119STS | |
| SCHEMBL1622025 | 0.93 | JAK2 (0.60) | JAK2JAK1USP30GPR119STS | |
| SCHEMBL8237687 | 0.84 | ACKR3 (0.57) | JAK2JAK1ACKR3HTR6USP30 | |
| SCHEMBL6214983 | 0.84 | ACKR3 (0.57) | JAK2JAK1ACKR3HTR6USP30 | |
| SCHEMBL15626828 | 0.83 | JAK2 (0.54) | JAK2JAK1USP30GPR119STS | |
| SCHEMBL13777209 | 0.82 | ACKR3 (0.53) | JAK2JAK1ACKR3HTR6USP30 | |
| SCHEMBL14720186 | 0.82 | JAK2 (0.52) | JAK2JAK1USP30GPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283354-B2 | Voltage gated sodium and calcium channel inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-09 | — | — | US | disclosed |
| US-7928107-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-19 | — | — | US | disclosed |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | JAK2 3157/4885JAK1 4357/4885ACKR3 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.